Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initiatives and commercialization efforts.” A well-known business executive in the pharma and biotech industries, Hawryluk currently serves as executive vice president and chief business officer of Gritstone bio, Inc. (NASDAQ: GRTS). Prior to moving to Gritstone, Hawryluk filled a variety of business-development, marketing and product-management roles, including VP of corporate and business development at Foundation Medicine Inc., a public molecular information company, which was subsequently acquired by Roche. Hawryluk has been instrumental in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. He is a named inventor on multiple patents and has coauthored several peer-reviewed publications. “Given his deep understanding of the biopharma landscape and his years of experience launching innovative platforms that have now been run on hundreds of thousands of patients with more than 20 FDA approvals, Matthew is both a logical and strategic addition to our Board,” said Predictive Oncology CEO and board chair Raymond F. Vennare in the press release. “In the business of drug discovery, relationships, reputation and industry reach are invaluable attributes, all of which Matthew possesses.”
To view the full press release, visit https://ibn.fm/oiDU4
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000-plus cancer tumors, categorized by patient type, against drug compounds to help the drug-discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
